CompletedPhase 1ACTRN12605000522617
A phase I pharmacokinetic study to compare the steady-state pharmacokinetics of testosterone following application of a Testosterone Metered-Dose Transdermal Spray (MDTS) to the forearm or abdomen in healthy postmenopausal women with low libido and low serum testosterone
Sponsor
FemPharm Pty Ltd and/or Acrux DDS Pty Ltd
Enrollment
14 participants
Start Date
Aug 8, 2002
Study Type
Interventional
Conditions
Eligibility
Sex: FemalesMin Age: 18 Yearss
Inclusion Criteria1
- Healthy post-menopausal women
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Testosterone Metered-Dose Transdermal Spray (MDTS), 5-days.
Testosterone Metered-Dose Transdermal Spray (MDTS), 5-days.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000522617